Center Mission: Therapy CoE is an organizational component within the SNMMI dedicated to all aspects of the development and utilization of Targeted Radioisotope Therapy (TRT) as an alternative to other treatments. Specifically, the center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

The Therapy Center of Excellence:
(a) Provides a forum for members with similar interests
(b) Provides expertise in TRT
(c) Fosters research and education in TRT
(d) Provides outreach to other professionals and organizations
(e) Nurtures new membership in SNMMI

Center Mission and SNMMI's Strategic Plan: The work of the Therapy Center applies to the following goals and objectives in SNMMI’s Strategic Plan:

Goal A: SNMMI members are known for high-quality, value-driven performance and delivery of patient-centered nuclear medicine practice.
   Objective 4. Expand continuing education options for practitioners.

Goal B: SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.
   Objective 1: Encourage and promote research in the field
   Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.

Goal E: Patients and the medical community recognize the value of nuclear medicine, molecular imaging and radionuclide therapy.
   Objective 3. Improve collaboration with other medical societies.
Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

   Objective 1: Strengthen membership numbers.
      d. Ensure enthusiasm.
         iii. Create a sense of community and networking opportunities among our members.

Therapy CoE President: Dan Pryma, MD

SNMMI Board members appointed to Therapy CoE Board: Bennett S. Greenspan, MD, FACNM, FACR; Jon Baldwin, DO; Suzanne Lapi, PhD

Date of Last meeting: January 27, 2018

Date of Next meeting: June 26, 2018

Update on Programs of the Center:

2018 SNMMI Annual Meeting Categorical Sessions:
   • CAT 1: Radioiodine Theragnostics - Continuing the Update of the Controversies of the Management of Differentiated Thyroid Cancer
   • CAT 3: PSMA Radioligand Therapy (PRLT) of End-Stage Prostate Cancer Patients Selected by PSMA PET/CT. The Power of Precision Oncology

2018 SNMMI Annual Meeting CE Session:
   • CE08: Theranostics and Bone Targeting Radiopharmaceutical Therapy in Prostate Cancer
   • CE15: Differentiated Thyroid Cancer Theranostics Practicum
   • CE22: Alpha-Emitting Radiopharmaceuticals
   • CE43: Saul Hertz Award Symposium: Emerging Theranostic Targets
   • CE50: Liver Directed Therapy
   • CE57: Theranostics of Neuroendocrine Tumors: PRRT

Outreach by Committee on Radioiodine Theragnostics (CORT):
   • 2018 Ohio State University Mazzaferri Symposium: SNMMI has been invited and accepted to have a nuclear medicine physicians speak at the Ohio State University Mazzaferri Symposium on 2 and 4 November 2018
Action Items in Progress/Pending:

- Launching additional committees of the Center
- Establishing the Therapy Center newsletter
- Planning a TRT Dosimetry Workshop with CTN and NCI, fall 2018
- ThyCa Initiative: bringing together local nuclear medicine physicians and ThyCa chapter facilitators to coordinate pro bono presentations by nuclear medicine physician in the region of the various ThyCa chapters on radioiodine imaging and therapy. Develop educational modules for these speakers.
- Multilateral Conference on Thyroid: White Paper and second conference

Action Items Completed: See programs above

Recommendations/Questions for the Board of Directors: N/A

Other Comments: N/A